Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 3/2010

01.05.2010

Current Management of Hepatocellular Cancer

verfasst von: Bernardino Rampone, Beniamino Schiavone, Giuseppe Confuorto

Erschienen in: Current Oncology Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, being the fifth most frequent cancer worldwide. It usually occurs in the setting of chronic liver disease and has a poor prognosis if untreated. Following the diagnosis, this disease requires multidisciplinary management. Orthotopic liver transplantation is theoretically the best treatment for early, unresectable HCC. However, the major practical obstacle is the extreme shortage of organs, which makes this a practical option only in selected patients. In this report we describe new advancements in diagnosis, classification, and treatment that have emerged in the field of HCC in recent years.
Literatur
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153–156.CrossRefPubMed
2.
Befeler AS, Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609–1619.CrossRefPubMed
3.
• Liu CJ, Kao JH: Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc 2007, 70:141–145. This is an interesting review on epidemiology and the pathogenic role of viral factors in hepatocarcinogenesis. CrossRefPubMed
4.
Fong TL, Kanel GC, Conrad A, et al.: Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994, 19:554–557.CrossRefPubMed
5.
Ming L, Thorgeirsson SS, Gail MH, et al.: Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002, 36:1214–1220.CrossRefPubMed
6.
Hassan MM, Hwang LY, Hatten CJ, et al.: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002, 36:1206–1213.CrossRefPubMed
7.
Ohata K, Hamasaki K, Toriyama K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036–3043.CrossRefPubMed
8.
Davila JA, Morgan RO, Shaib Y, et al.: Diabetes has been found to increase the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54:533–539.CrossRefPubMed
9.
Kew MC: The development of hepatocellular cancer in humans. Cancer Surv 1986, 5:719–739.PubMed
10.
11.
El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74–S83.CrossRefPubMed
12.
Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942–1956.CrossRefPubMed
13.
El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745–750.CrossRefPubMed
14.
Allen J, Venook A: Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004, 6:177–183.CrossRefPubMed
15.
Tanaka Y, Hanada K, Mizokami M, et al.: Inaugural article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002, 99:15584–15589.CrossRefPubMed
16.
• Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362:1907–1917. This is a positive paper on management of HCC.CrossRefPubMed
17.
Makuuchi M, Sano K: The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004, 10:46–52.CrossRef
18.
19.
•• Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693–699. This study introduced the Milan criteria and showed that liver transplantation is an effective treatment for small, unresectable HCC in patients with cirrhosis.CrossRefPubMed
20.
Llovet JM, Di Bisceglie AM, Bruix J, et al.: Design and endpoints of clinical trials in hepatocellular carcinoma. Panel of Experts in HCC-Design Clinical Trials. J Natl Cancer Inst 2008, 100:698–711.CrossRefPubMed
21.
Bruix J, Sherman M, Llovet JM, et al.: EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421–430.CrossRefPubMed
22.
Marrerro JA, Fontana RJ, Barrat A: Prognosis of hepatocellular carcinoma: comparison of 7 staging system in an American cohort. Hepatology 2005, 41:707–716.CrossRef
23.
Cillo U, Vitale A, Grigoletto F: Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006, 44:723–731.CrossRefPubMed
24.
•• Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378–390. This article shows that sorafenib improves overall survival for patients with advanced HCC.CrossRefPubMed
25.
Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312–1327.CrossRefPubMed
26.
Marin-Hargreaves G, Azoulay D, Bismuth H: Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol 2003, 47:13–27.CrossRefPubMed
27.
De Carlis L, Giacomoni A, Pirotta V, et al.: Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 2003, 196:887–897.CrossRefPubMed
28.
Vauthey JN, Chaoui A, Do KA, et al.: Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000, 127:512–519.CrossRefPubMed
29.
Farges O, Belghiti J, Kianmanesh R, et al.: Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003, 237:208–217.CrossRefPubMed
30.
Oldhafer KJ, Lang H, Malago M, et al.: Ex situ resection and resection of the in situ perfused liver: are there still indications? Chirurg 2001, 72:131–137.CrossRefPubMed
31.
Ringe B, Weimann A, Tusch G, Pichlmayr R: Resection versus transplantation for malignancy of liver and bile duct. In Surgery for Gastrointestinal Cancer. Edited by Wanebo HJ. Philadelphia: Lippincott-Raven; 1997:513–524.
32.
Bismuth H, Chiche L, Adam R, et al.: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993, 218:145–151.CrossRefPubMed
33.
Ojogho ON, So SK, Keeffe EB, et al.: Orthotopic liver transplantation for hepatocellular carcinoma. Factors affecting long-term patient survival. Arch Surg 1996, 131:935–939; discussion 939–941.PubMed
34.
Molmenti EP, Klintmalm GB: Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002, 8:736–748.CrossRefPubMed
35.
Plessier A, Codes L, Consigny Y, et al.: Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004, 10:S86–S90.CrossRefPubMed
36.
Pawlik TM, Delman KA, Vauthey JN, et al.: Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005, 11:1086–1092.CrossRefPubMed
37.
Jonas S, Bechstein WO, Steinmuller T, et al.: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 5:1080–1086.CrossRef
38.
Bruix J, Fuster J, Llovet JM: Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 2003, 7:700–702.CrossRef
39.
Yao FY, Bass NM, Nikolai B, et al.: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002, 8:873–883.CrossRefPubMed
40.
Yao FY, Xiao L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007, 7:2587–2596.CrossRefPubMed
41.
•• Mazzaferro V, Llovet JM, Miceli R, et al.; Metroticket Investigator Study Group: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35–43. This study showed that more patients with HCC could be candidates for transplantation if the current dual (yes/no) approach to candidacy, based on the strict Milan criteria, was replaced with a more precise estimation of survival contouring individual tumor characteristics and use of the up-to-seven criteria. CrossRefPubMed
42.
Sarasin FP, Giostra E, Mentha G, Hadengue A: Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology 1998, 28:436–442.CrossRefPubMed
43.
Saab S, Wang V, Ibrahim AB, et al.: MELD score predict 1-years patient survival post-orthotopic liver transplantation. Liver Transpl 2003, 9:473–476.CrossRefPubMed
44.
Yao FY, Bass NM, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: Lesson from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 2004, 10:621–630.CrossRefPubMed
45.
Ryu M, Shimamura Y, Kinoshita T, et al.: Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol 1997, 27:251–257.CrossRefPubMed
46.
Livraghi T, Solbiati L, Meloni MF, et al.: Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003, 226:441–451.CrossRefPubMed
47.
• Poon RT, Fan ST, Tsang FH, Wong J: Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 2002, 235:466–486. This article details how recent advances in locoregional therapies have led to a major breakthrough in the management of HCC.CrossRefPubMed
48.
Van Kleek EJ, Schwartz JM, Rayhill SC, et al.: Liver transplantation for hepatocellular carcinoma: a survey of practices. J Clin Gastroenterol 2006, 40:643–647.CrossRefPubMed
49.
Broering DC, Wilms C, Bok P, et al.: Evolution of donor morbidity in living related liver transplantation: a single-center analysis of 165 cases. Ann Surg 2004, 240:1013–1024; discussion 1024–1026.CrossRefPubMed
50.
• Trotter JF, Wachs M, Everson GT, Kam I: Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002, 346:1074–1082. LDLT has rapidly emerged as an accepted treatment option for selected patients with end-stage liver disease.CrossRefPubMed
Metadaten
Titel
Current Management of Hepatocellular Cancer
verfasst von
Bernardino Rampone
Beniamino Schiavone
Giuseppe Confuorto
Publikationsdatum
01.05.2010
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 3/2010
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0094-3

Weitere Artikel der Ausgabe 3/2010

Current Oncology Reports 3/2010 Zur Ausgabe

ReviewPaper

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma

ReviewPaper

KRAS Testing and Its Importance in Colorectal Cancer

ReviewPaper

Proton Beam Radiation Therapy for Head and Neck Malignancies

ReviewPaper

Evolving Treatment of Advanced Colorectal Cancer

ReviewPaper

Advances in Quality of Life Research Among Head and Neck Cancer Patients

ReviewPaper

Current and Emerging Treatment Strategies for Anal Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise